Last reviewed · How we verify

Regional analgesia and propofol

The Cleveland Clinic · Phase 3 active Small molecule

Regional analgesia with propofol combines local anesthetic nerve blockade with intravenous sedation to provide perioperative pain control and anxiolysis.

Regional analgesia with propofol combines local anesthetic nerve blockade with intravenous sedation to provide perioperative pain control and anxiolysis. Used for Perioperative analgesia and sedation during surgical procedures.

At a glance

Generic nameRegional analgesia and propofol
Also known asRegional analgesia
SponsorThe Cleveland Clinic
Drug classLocal anesthetic + sedative-hypnotic combination
ModalitySmall molecule
Therapeutic areaAnesthesiology / Perioperative Medicine
PhasePhase 3

Mechanism of action

Regional anesthesia techniques (such as peripheral nerve blocks or neuraxial blockade) deliver local anesthetics directly to target nerves to block pain transmission in a specific anatomical region. Propofol is a rapid-acting intravenous sedative-hypnotic that enhances GABAergic inhibition in the central nervous system. Together, this combination approach reduces systemic opioid requirements and provides both local pain relief and conscious sedation during surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: